Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Breathing in wildfire pollution may make it harder for people with lung cancer to survive, according to a new study from UC ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Stage 3 lung cancer is considered locally advanced with spread in the region near the site. Survival rates for stage 3 non-small cell lung cancer (NSCLC) range from as high as 36% to as low as 13% ...

Amidst the continued struggle to treat non-small-cell lung cancer, a new study led by Stanford University scientists suggests that a patient's response to immunotherapy may hinge on how immune cells ...

Still, the therapies’ modest benefit as a maintenance therapy points to how better treatments are needed for small cell lung ...

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...

Health Canada has granted a Notice of Compliance with conditions (NOC/c) for Tagrisso® (osimertinib) for the treatment of patients with locally advanced, unresectable (stage III) non-small cell lung ...

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous ...